Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?Rosalba Torrisi, Armando Santoro, Emilia Marrazzo et al.|Critical Reviews in Oncology/Hematology|2021Cited by 63
Pregnancy After Breast Cancer in Young <i>BRCA </i>CarriersMatteo Lambertini, Young‐Jin Lee, Stephanie M. Wong et al.|JAMA|2023Cited by 57
Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?Rosalba Torrisi, Armando Santoro, Monica Zuradelli et al.|Critical Reviews in Oncology/Hematology|2019Cited by 33
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Lucia Del Mastro, Eva Blondeaux et al.|EClinicalMedicine|2023Cited by 28
Hope and Hype around Immunotherapy in Triple-Negative Breast CancerFlavia Jacobs, Armando Santoro, Elisa Agostinetto et al.|Cancers|2023Cited by 20